~~<i id='914612A6CB'><strike id='914612A6CB'><tt id='914612A6CB'><pre id='914612A6CB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

explore

author：comprehensive 2025-10-01 00:58:32 - browse：98

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Health officials lay out plans to cope with respiratory virus season

explore

leisure time

knowledge

Wikipedia

leisure time

focus

MollyFergusonforSTATAmericanmedicineisatragicparadox.Anexample:Cancerpatientsarelikelydyingasaresult

WSS

WATCH: Why do our ears pop?

MD Anderson's Padmanee Sharma responds to research credit suit

As AI regulations shape up, health tech startups beg for clarity

New CMS data security rules will hurt Medicare, Medicaid research

A new drug could help frostbite victims avoid its ravages

Secretariat’s lessons for human medicine

leisure time

explore

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Health officials lay out plans to cope with respiratory virus season

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Listen: Vivek Ramaswamy's star turn & leaky drug data

Activists slam private health insurers over coverage restrictions

Kellogg’s is going to war over Mexico’s nutrition label rules

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Meadows told special counsel he could not recall Trump ever declassifying Mar

Supreme Court strikes down use of affirmative action

California store owner shot dead in dispute over displaying Pride flag: Police

leisure time

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Reporting on presidential health from Reagan to Trump and Biden

Ukraine seeks to reclaim its role as a hub for clinical trials

Flagship Pioneering startup Sonata Therapeutics lays off 21

DeSantis wants to import drugs. Biden’s FDA blasted his plan

DeSantis wants to import drugs. Biden’s FDA blasted his plan

knowledge

Wikipedia

leisure time

focus